ABBV - AbbVie Inc.

QQQ $ 494.79 $ 2.89 (0.59 %)

DIA $ 400.37 $ 2.69 (0.68 %)

SPY $ 559.91 $ 3.51 (0.63 %)

TLT $ 93.88 $ 0.40 (0.43 %)

GLD $ 223.10 $ -0.14 (-0.06 %)

Previous Close

$ 170.28

Open

$ 170.65

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 169.91 - $ 171.59

52 Week Range

$ 128.94 - $ 181.20

Volume

4,133,520

Average Volume

Market Cap

301.91B

Beta (5Y Monthly)

$ 0.64

PE Ratio (TTM)

$ 50.38

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.04)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-03-2024	03-31-2024	10-Q
2	02-20-2024	12-31-2023	10-K
3	11-06-2023	09-30-2023	10-Q
4	08-07-2023	06-30-2023	10-Q
5	05-05-2023	03-31-2023	10-Q
6	02-17-2023	12-31-2022	10-K
7	11-04-2022	09-30-2022	10-Q
8	08-04-2022	06-30-2022	10-Q
9	05-06-2022	03-31-2022	10-Q
10	02-18-2022	12-31-2021	10-K
11	11-02-2021	09-30-2021	10-Q
12	08-02-2021	06-30-2021	10-Q
13	05-07-2021	03-31-2021	10-Q
14	02-19-2021	12-31-2020	10-K
15	11-04-2020	09-30-2020	10-Q
16	08-04-2020	06-30-2020	10-Q
17	05-08-2020	03-31-2020	10-Q
18	02-21-2020	12-31-2019	10-K
19	11-06-2019	09-30-2019	10-Q
20	08-05-2019	06-30-2019	10-Q
21	05-03-2019	03-31-2019	10-Q
22	02-27-2019	12-31-2018	10-K
23	11-07-2018	09-30-2018	10-Q
24	08-07-2018	06-30-2018	10-Q
25	05-04-2018	03-31-2018	10-Q
26	02-16-2018	12-31-2017	10-K
27	11-07-2017	09-30-2017	10-Q
28	08-07-2017	06-30-2017	10-Q
29	05-05-2017	03-31-2017	10-Q
30	02-17-2017	12-31-2016	10-K
31	11-07-2016	09-30-2016	10-Q
32	08-05-2016	06-30-2016	10-Q
33	05-06-2016	03-31-2016	10-Q
34	02-19-2016	12-31-2015	10-K
35	11-06-2015	09-30-2015	10-Q
36	08-07-2015	06-30-2015	10-Q
37	05-08-2015	03-31-2015	10-Q
38	02-20-2015	12-31-2014	10-K
39	11-07-2014	09-30-2014	10-Q
40	08-07-2014	06-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

abbvie-appeals-to-supreme-court-over-attorney-client-privilege-in-long-standing-androgel-case

AbbVie Appeals To Supreme Court Over Attor...
07/12/2024 17:39:05

AbbVie petitions the U.S. Supreme Court to protect its corporate records, arguing a lower court ruling threatens attorney-clien...

AbbVie Submits Applications To FDA And EMA...
07/12/2024 12:32:29

is-big-pharma-poised-to-take-over-cannabis-3-companies-already-manage-8-in-10-drug-prescriptions-in-the-us

Is Big Pharma Poised To Take Over Cannabis...
07/11/2024 19:01:01

The U.S. Federal Trade Commission (FTC) recently highlighted the significant influence of pharmacy benefit managers (PBMs) on d...

AbbVie Unusual Options Activity
07/11/2024 18:47:30

Morgan Stanley Maintains Overweight on Abb...
07/11/2024 17:13:06

Morgan Stanley analyst Terence Flynn maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $191 to...

10-health-care-stocks-whale-activity-in-todays-session

10 Health Care Stocks Whale Activity In To...
07/10/2024 17:35:24

Cantor Fitzgerald Reiterates Overweight on...
07/09/2024 13:20:41

Cantor Fitzgerald analyst Louise Chen reiterates AbbVie (NYSE:ABBV) with a Overweight and maintains $200 price target.

1000-invested-in-abbvie-10-years-ago-would-be-worth-this-much-today

$1000 Invested In AbbVie 10 Years Ago Woul...
07/08/2024 14:00:28

a-closer-look-at-abbvies-options-market-dynamics

A Closer Look at AbbVie's Options Market D...
07/03/2024 16:46:42

Watching Cerevel Therapeutics; Traders Cir...
07/03/2024 15:27:18

A Glimpse Into The Expert Outlook On AbbVi...
07/02/2024 18:00:25

Piper Sandler Maintains Overweight on AbbV...
07/02/2024 17:23:45

Piper Sandler analyst Christopher Raymond maintains AbbVie (NYSE:ABBV) with a Overweight and maintains $190 price target.

AbbVie Names Robert A. Michael CEO; Richar...
07/01/2024 12:11:06

As Previously Announced, Richard A. Gonzalez Retires as Chief Executive Officer to Become Executive ChairmanRobert A. Michael J...

Reported Earlier, AbbVie's Epcoritamab Rec...
06/28/2024 07:38:13

AbbVie (NYSE:ABBV) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Us...

abbviegenmabs-epkinly-fda-approval-is-a-positive-step-analyst-says-additional-expansion-opportunities-underway

AbbVie/Genmab's Epkinly FDA Approval Is A ...
06/27/2024 17:22:09

The FDA has approved Epkinly as the first subcutaneously administered bispecific antibody for adults with relapsed or refractor...

looking-at-abbvies-recent-unusual-options-activity

Looking At AbbVie's Recent Unusual Options...
06/27/2024 16:03:25

AbbVie Acquires Celsius Therapeutics Acqui...
06/27/2024 13:28:39

Celsius' CEL383 is a potential first-in-class anti-Triggering Receptor Expressed on Myeloid Cells 1 (TREM1) antibody for th...

Allergan Aesthetics Debuts Allē Payment Pl...
06/27/2024 12:32:58

$abbvie-announced-that-the-us-fda-has-approved-epkinly-as-the-first-and-only-t-cell-engaging-bispecific-antibody-administered-subcutaneously-for-the-treatment-of-adults-with-relapsed-or-refractory-follicular-lymphoma$

AbbVie Announced That The U.S. FDA Has App...
06/27/2024 06:50:48